Table 1.
Year | Shortages with an equivalent drug | Shortages without an equivalent | Cases due to permanent discontinuation |
---|---|---|---|
2018 | 74.5% (n = 1205) | 25.5% (n = 412) | 50.7% (n = 821) |
2019 | 76.3% (n = 1638) | 23.6% (n = 507) | 45.2% (n = 970) |
2020 | 78.3% (n = 2042) | 21.7% (n = 565) | 41.6% (n = 1084) |
2021 | 77.1% (n = 1868) | 22.9% (n = 554) | 49.7% (n = 1204) |
2022 | 77.7% (n = 2175) | 22.3% (n = 623) | 49.7% (n = 1302) |
2023 | 78.4% (n = 2629) | 21.6% (n = 744) | 42% (n = 1417) |
2024 | 78.4% (n = 2881) | 21.6% (n = 771) | 42% (n = 1566) |